Lucatumumab
Alternative Names: CHIR-12.12; HCD-122Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis; XOMA
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Multiple myeloma
Most Recent Events
- 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in Belgium (IV)
- 23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in USA (IV)
- 23 Jan 2013 Discontinued - Phase-I/II for Lymphoma in Australia (IV)